Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Thursday

Tyra Biosciences (NASDAQ:TYRA) will likely be announcing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 2, 2026 at 3:00 PM ET.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.03). On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tyra Biosciences Stock Up 0.3%

NASDAQ:TYRA opened at $38.05 on Thursday. The firm has a market capitalization of $2.05 billion, a P/E ratio of -18.93 and a beta of 1.06. The company has a fifty day moving average of $31.80 and a 200 day moving average of $22.56. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $38.53.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of Tyra Biosciences stock in a transaction on Friday, December 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director owned 3,823,425 shares in the company, valued at approximately $95,585,625. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 15.20% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

Large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd bought a new position in Tyra Biosciences in the 4th quarter worth about $51,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Tyra Biosciences by 14.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Tyra Biosciences by 27.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after purchasing an additional 2,766 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in Tyra Biosciences in the fourth quarter worth about $220,000. Finally, VARCOV Co. purchased a new position in Tyra Biosciences in the fourth quarter worth about $255,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

TYRA has been the topic of several recent research reports. Wall Street Zen downgraded Tyra Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. Cantor Fitzgerald began coverage on shares of Tyra Biosciences in a report on Tuesday, February 24th. They set an “overweight” rating on the stock. Jefferies Financial Group upped their target price on shares of Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. Barclays initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, January 27th. They issued an “overweight” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tyra Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $42.33.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.